Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
24
JDHIY Quote, Financials, Valuation and Earnings
Last price:
$7.25
Seasonality move
:
-20.49%
Day range:
$7.25 - $7.25
52-week range:
$3.81 - $9.08
Dividend yield:
0%
P/E ratio:
35.25x
P/S ratio:
2.55x
P/B ratio:
2.88x
Volume:
--
Avg. volume:
9
1-year change:
90.29%
Market cap:
$23.2B
Revenue:
$8.1B
EPS (TTM):
$0.21
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JDHIY
JD Health International, Inc.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$138M | -$0.28 | 16.18% | -46.43% | $49.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JDHIY
JD Health International, Inc.
|
$7.25 | -- | $23.2B | 35.25x | $0.00 | 0% | 2.55x |
|
ADAG
Adagene, Inc.
|
$1.79 | $9.22 | $84.3M | -- | $0.00 | 0% | 805.60x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.77 | $4.00 | $15.9M | -- | $0.00 | 0% | 0.45x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.24 | -- | $4M | -- | $0.00 | 0% | 1.00x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$17.82 | $49.17 | $2B | -- | $0.00 | 0% | 4.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JDHIY
JD Health International, Inc.
|
-- | 1.698 | -- | 3.39x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JDHIY
JD Health International, Inc.
|
-- | -- | 8% | 8% | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
JD Health International, Inc. vs. Competitors
-
Which has Higher Returns JDHIY or ADAG?
Adagene, Inc. has a net margin of -- compared to JD Health International, Inc.'s net margin of --. JD Health International, Inc.'s return on equity of 8% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital JDHIYJD Health International, Inc.-- -- $7.6B ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About JDHIY or ADAG?
JD Health International, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 415.32%. Given that Adagene, Inc. has higher upside potential than JD Health International, Inc., analysts believe Adagene, Inc. is more attractive than JD Health International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JDHIYJD Health International, Inc.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is JDHIY or ADAG More Risky?
JD Health International, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock JDHIY or ADAG?
JD Health International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. JD Health International, Inc. pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JDHIY or ADAG?
JD Health International, Inc. quarterly revenues are --, which are smaller than Adagene, Inc. quarterly revenues of --. JD Health International, Inc.'s net income of -- is lower than Adagene, Inc.'s net income of --. Notably, JD Health International, Inc.'s price-to-earnings ratio is 35.25x while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JD Health International, Inc. is 2.55x versus 805.60x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDHIYJD Health International, Inc.2.55x 35.25x -- -- ADAGAdagene, Inc.805.60x -- -- --
-
Which has Higher Returns JDHIY or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -- compared to JD Health International, Inc.'s net margin of -353.92%. JD Health International, Inc.'s return on equity of 8% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital JDHIYJD Health International, Inc.-- -- $7.6B CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About JDHIY or CASI?
JD Health International, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 417.6%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than JD Health International, Inc., analysts believe CASI Pharmaceuticals, Inc. is more attractive than JD Health International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JDHIYJD Health International, Inc.0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is JDHIY or CASI More Risky?
JD Health International, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock JDHIY or CASI?
JD Health International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. JD Health International, Inc. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JDHIY or CASI?
JD Health International, Inc. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. JD Health International, Inc.'s net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, JD Health International, Inc.'s price-to-earnings ratio is 35.25x while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JD Health International, Inc. is 2.55x versus 0.45x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDHIYJD Health International, Inc.2.55x 35.25x -- -- CASICASI Pharmaceuticals, Inc.0.45x -- $3.1M -$10.9M
-
Which has Higher Returns JDHIY or CPHI?
China Pharma Holdings, Inc. has a net margin of -- compared to JD Health International, Inc.'s net margin of -86.16%. JD Health International, Inc.'s return on equity of 8% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital JDHIYJD Health International, Inc.-- -- $7.6B CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About JDHIY or CPHI?
JD Health International, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that JD Health International, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe JD Health International, Inc. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JDHIYJD Health International, Inc.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is JDHIY or CPHI More Risky?
JD Health International, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock JDHIY or CPHI?
JD Health International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. JD Health International, Inc. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JDHIY or CPHI?
JD Health International, Inc. quarterly revenues are --, which are smaller than China Pharma Holdings, Inc. quarterly revenues of $756.2K. JD Health International, Inc.'s net income of -- is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, JD Health International, Inc.'s price-to-earnings ratio is 35.25x while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JD Health International, Inc. is 2.55x versus 1.00x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDHIYJD Health International, Inc.2.55x 35.25x -- -- CPHIChina Pharma Holdings, Inc.1.00x -- $756.2K -$651.5K
-
Which has Higher Returns JDHIY or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to JD Health International, Inc.'s net margin of --. JD Health International, Inc.'s return on equity of 8% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital JDHIYJD Health International, Inc.-- -- $7.6B SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About JDHIY or SVA?
JD Health International, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that JD Health International, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe JD Health International, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings JDHIYJD Health International, Inc.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is JDHIY or SVA More Risky?
JD Health International, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock JDHIY or SVA?
JD Health International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. JD Health International, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios JDHIY or SVA?
JD Health International, Inc. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. JD Health International, Inc.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, JD Health International, Inc.'s price-to-earnings ratio is 35.25x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JD Health International, Inc. is 2.55x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDHIYJD Health International, Inc.2.55x 35.25x -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns JDHIY or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to JD Health International, Inc.'s net margin of -30.98%. JD Health International, Inc.'s return on equity of 8% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital JDHIYJD Health International, Inc.-- -- $7.6B ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About JDHIY or ZLAB?
JD Health International, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.17 which suggests that it could grow by 175.93%. Given that Zai Lab Ltd. has higher upside potential than JD Health International, Inc., analysts believe Zai Lab Ltd. is more attractive than JD Health International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JDHIYJD Health International, Inc.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is JDHIY or ZLAB More Risky?
JD Health International, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock JDHIY or ZLAB?
JD Health International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. JD Health International, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JDHIY or ZLAB?
JD Health International, Inc. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. JD Health International, Inc.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, JD Health International, Inc.'s price-to-earnings ratio is 35.25x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JD Health International, Inc. is 2.55x versus 4.33x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDHIYJD Health International, Inc.2.55x 35.25x -- -- ZLABZai Lab Ltd.4.33x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 41.08% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 2.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 5.28% over the past day.
